Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emivirine: an NRTI that functions as an NNRTI.

BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation - 1 Jan 1999

Cheonis N

Abstract excerpt

Emivirine (MKC-442) structurally is a nucleoside analog (NRTI) molecule, but it functions as a non-nucleoside reverse transcriptase inhibitor (NNRTI). It inhibits HIV replication by binding to the reverse transcriptase viral enzyme. The drug is classified as an NNRTI and is the only anti-HIV drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cesarean Section
Share to Clinical Trials as Topic
Share to Drug Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drugs, Investigational

Share to Infectious Disease Transmission, Vertical

Share to Pregnancy Complications, Infectious

Share to Reverse Transcriptase Inhibitors

Share to Uracil

Source

Identifiers

PMID: 11367264

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-11367264-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emivirine: an NRTI that functions as an NNRTI.PMID 11367264Read ↗

Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitroSemantic proximity Read ↗

The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase InhibitorsSemantic proximity Read ↗

Clinical Utility of Current NNRTIs and Perspectives of New Agents in This Class under DevelopmentSemantic proximity Read ↗

In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.Semantic proximity Read ↗

Clinical uses of non-nucleoside reverse transcriptase inhibitorsSemantic proximity Read ↗

New nonnucleoside reverse transcriptase inhibitors.Semantic proximity Read ↗

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.Semantic proximity Read ↗

Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties.Semantic proximity Read ↗

Antiviral Activity of MK-4965, a Novel Nonnucleoside Reverse Transcriptase InhibitorSemantic proximity Read ↗

Emerging Pharmacology: Inhibitors of Human Immunodeficiency Virus IntegrationSemantic proximity Read ↗

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1Semantic proximity Read ↗

Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.